Home
Abstract
My Abstract(s)
Login
ePosters
Back
Final Presentation Format
Podium Abstract
Eposter Presentation
Eposter in PDF Format
Accept format: PDF. The file size should not be more than 5MB
Eposter in Image Format
Accept format: PNG/JPG/WEBP. The file size should not be more than 2MB
Presentation Date / Time
Submission Status
Submitted
Abstract
Abstract Title
1-Monopalmitin inhibits benign prostatic hyperplasia by suppressing endoplasmic reticulum stress and androgen receptor
Presentation Type
Podium Abstract
Manuscript Type
Basic Research
Abstract Category *
Benign Prostate Hyperplasia and Male Lower Urinary Tract Symptoms: Medical Treatment
Author's Information
Number of Authors (including submitting/presenting author) *
2
No more than 10 authors can be listed (as per the Good Publication Practice (GPP) Guidelines).
Please ensure the authors are listed in the right order.
Country
China
Co-author 1
Changyu Zhang zhangchunyu2019@163.com Tongji hospital Urology Wuhan China *
Co-author 2
Zhihua Wang zhwang_hust@hotmail.com Tongji hospital Urology Wuhan China -
Co-author 3
-
Co-author 4
-
Co-author 5
-
Co-author 6
-
Co-author 7
-
Co-author 8
-
Co-author 9
-
Co-author 10
-
Co-author 11
-
Co-author 12
-
Co-author 13
-
Co-author 14
-
Co-author 15
-
Co-author 16
-
Co-author 17
-
Co-author 18
-
Co-author 19
-
Co-author 20
-
Abstract Content
Introduction
1-Monopalmitin (1-Mono) is the principal active component found in natural plants such as Mougeotia nummuloides and Spirulina major, which has been shown to promote apoptosis in lung cancer cells through the PI3K/AKT pathway. However, the effects of 1-Mono on benign prostatic hyperplasia (BPH) remain unclear. This study aims to investigate the therapeutic effects of 1-Mono in BPH models and its underlying molecular mechanisms.
Materials and Methods
This study first utilized two-sample Mendelian randomization to screen for key metabolites with a causal relationship to BPH from 486 serum metabolites, identifying 1-Mono. Subsequently, various in vitro techniques, including CCK-8, EdU assays, apoptosis detection, Western Blot (WB), and qRT-PCR, were employed to evaluate the effects of 1-Mono on proliferation, apoptosis, and inflammatory responses in BPH-1 and WPMY-1 cells. In vivo, a rat BPH model was established, and the impact of 1-Mono on prostate enlargement and cell proliferation was assessed through H&E staining, immunohistochemistry, immunofluorescence, and WB. Mechanistic studies were conducted using RNA sequencing, molecular docking, and rescue experiments to explore the regulatory mechanisms of 1-Mono in BPH.
Results
The study found that elevated genetic susceptibility levels of 1-Mono significantly reduced susceptibility to BPH. In vitro experiments demonstrated that 1-Mono significantly inhibited proliferation and inflammatory responses in BPH-1 and WPMY-1 cells while promoting apoptosis. In the testosterone-induced BPH rat model, 1-Mono effectively alleviated pathological prostate enlargement. Mechanistic studies revealed that 1-Mono inhibited the androgen/androgen receptor (AR) signaling pathway and suppressed the upregulation of pro-inflammatory molecules by alleviating endoplasmic reticulum stress (ER-stress). AR knockdown experiments partially abolished the beneficial effects of 1-Mono in prostate cells, indicating that its action is AR-dependent.
Conclusions
As an inhibitor of AR and ER-stress, 1-Mono demonstrates considerable therapeutic potential and may serve as an effective treatment for BPH.
Keywords
1-Monopalmitin, benign prostatic hyperplasia, endoplasmic reticulum stress, androgen receptor
Figure 1
Figure 1 Caption
Figure 2
Figure 2 Caption
Figure 3
Figure 3 Caption
Figure 4
Figure 4 Caption
Figure 5
Figure 5 Caption
Character Count
2102
Vimeo Link
Presentation Details
Session
Free Paper Podium(21): BPH & Novel Advances (B)
Date
Aug. 17 (Sun.)
Time
11:54 - 12:00
Presentation Order
15